Tagged with NASH

Global After a 12-year stint at Sanofi, Bill Sibold is leaving Big Pharma to join the Pennsylvania-based biotech Madrigal Pharmaceuticals as CEO. Sibold, no stranger to ground-breaking launches, having brought the blockbuster Dupixent to market, will be coming onboard just ahead of what looks to be a pivotal moment for Madrigal.…

France Inventiva is a French clinical-stage biotech company focused on developing oral small molecule epigenetic modulators in therapeutic areas with high unmet medical needs such as fibrosis, lysosomal storage disorders and oncology. Its most advanced program is a first-in-class drug candidate against NASH. Inventiva’s chairman, CEO and co-founder, Frédéric Cren, explains…

China Terns Pharmaceuticals is developing innovative drugs for the treatment of NASH and liver disease. It has established a diverse product pipeline with drug candidates targeting different stages of the disease and with complementary mechanisms of action, through partnerships with global pharma companies as well as in-house discovery efforts. With offices…

Pharma Genfit’s Jean-François Mouney speaks about responding to high unmet medical needs in inflammatory and metabolic related diseases. With the increase in obesity related diseases, Mouney discusses their lead pipeline product: Elafibranor, the new orphan blockbuster drug aimed at curing NASH; nonalcoholic steatohepatitis and other related diseases.   As an entrepreneur…

Monash University Professor Kenneth K. C. Lee, Head of the School of Pharmacy at Monash University Malaysia, discusses the institution’s position as a hub for health economics in the Asia Pacific region and explains the factors that will make the university a pharmaceutical leader.   There is a lot of competition in…